AIMS AND BACKGROUND: The treatment of unresectable cancers is still one of the main medical challenges. Stop-flow perfusion has been used as locoregional chemotherapy based on blood supply blockage of the tumor-bearing area. The aim of the present paper is to report our personal experience in the clinical use of hypoxic stop-flow perfusion and discuss future prospects for research. METHODS AND STUDY DESIGN: Since December 1997 more than 500 stop-flow perfusions have been performed at the University of L'Aquila. Hypoxic perfusion was adopted for the following indications: recurrent rectal cancer, advanced pancreatic cancer, recurrent pelvic and limb melanoma, and recurrent limb melanoma. RESULTS: For recurrent rectal cancer median survival was 12.2 months, for advanced pancreatic cancer 9.6 months, for recurrent pelvic and limb melanoma 34.4 months, and for recurrent limb melanoma 23.8 months. CONCLUSIONS: Based on these encouraging results, stop-flow perfusion should be considered an effective treatment. Future fields of research include tailored chemotherapy and hyperthermia.
AIMS AND BACKGROUND: The treatment of unresectable cancers is still one of the main medical challenges. Stop-flow perfusion has been used as locoregional chemotherapy based on blood supply blockage of the tumor-bearing area. The aim of the present paper is to report our personal experience in the clinical use of hypoxic stop-flow perfusion and discuss future prospects for research. METHODS AND STUDY DESIGN: Since December 1997 more than 500 stop-flow perfusions have been performed at the University of L'Aquila. Hypoxic perfusion was adopted for the following indications: recurrent rectal cancer, advanced pancreatic cancer, recurrent pelvic and limb melanoma, and recurrent limb melanoma. RESULTS: For recurrent rectal cancer median survival was 12.2 months, for advanced pancreatic cancer 9.6 months, for recurrent pelvic and limb melanoma 34.4 months, and for recurrent limb melanoma 23.8 months. CONCLUSIONS: Based on these encouraging results, stop-flow perfusion should be considered an effective treatment. Future fields of research include tailored chemotherapy and hyperthermia.
Authors: Stefano Guadagni; Marco Clementi; Francesco Masedu; Giammaria Fiorentini; Donatella Sarti; Marcello Deraco; Shigeki Kusamura; Ioannis Papasotiriou; Panagiotis Apostolou; Karl Reinhard Aigner; Giuseppe Zavattieri; Antonietta Rossella Farina; Giuseppe Vizzielli; Giovanni Scambia; Andrew Reay Mackay Journal: Int J Mol Sci Date: 2020-07-07 Impact factor: 5.923
Authors: Stefano Guadagni; Giammaria Fiorentini; Andrea Mambrini; Francesco Masedu; Marco Valenti; Andrew Reay Mackay; Donatella Sarti; Enrico Ricevuto; Marco Clementi; Marco Catarci; Gianni Lazzarin; Gemma Bruera Journal: Oncotarget Date: 2019-06-11
Authors: Stefano Guadagni; Giammaria Fiorentini; Michele De Simone; Francesco Masedu; Odisseas Zoras; Andrew Reay Mackay; Donatella Sarti; Ioannis Papasotiriou; Panagiotis Apostolou; Marco Catarci; Marco Clementi; Enrico Ricevuto; Gemma Bruera Journal: J Cancer Res Clin Oncol Date: 2019-10-16 Impact factor: 4.553